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Pulmonary embolism: the diagnosis, 
risk-stratification, treatment and 
disposition of emergency department 
patients
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The diagnosis or exclusion of pulmonary embolism (PE) remains challenging for emergency phy-
sicians. Symptoms can be vague or non-existent, and the clinical presentation shares features 
with many other common diagnoses. Diagnostic testing is complicated, as biomarkers, like the 
D-dimer, are frequently false positive, and imaging, like computed tomography pulmonary angi-
ography, carries risks of radiation and contrast dye exposure. It is therefore incumbent on emer-
gency physicians to be both vigilant and thoughtful about this diagnosis. In recent years, several 
advances in treatment have also emerged. Novel, direct-acting oral anticoagulants make the 
outpatient treatment of low risk PE easier than before. However, the spectrum of PE severity 
varies widely, so emergency physicians must be able to risk-stratify patients to ensure the ap-
propriate disposition. Finally, PE response teams have been developed to facilitate rapid access 
to advanced therapies (e.g., catheter directed thrombolysis) for patients with high-risk PE. This 
review will discuss the clinical challenges of PE diagnosis, risk stratification and treatment that 
emergency physicians face every day. 
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What is already known
The diagnosis, risk-stratification and treatment of pulmonary embolism (PE) re-
mains challenging. Well defined systems exist to help emergency physicians 
identify patients who require testing. Diagnostic testing for PE must be ap-
proached thoughtfully, to maximize sensitivity while minimizing side-effects of 
testing. Novel anticoagulants and invasive procedures are changing the land-
scape of PE treatment.
What is new in the current study
This review will discuss the challenge of PE diagnosis, risk stratification and 
treatment - including the use of novel anticoagulants for the outpatient treat-
ment of low risk PE and the creation of PE response teams to facilitate advanc-
ed treatment for high risk PE.
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INTRODUCTION
Pulmonary embolism (PE) is the third most common cause of car-
diovascular death among Americans, behind myocardial infarc-
tion and stroke.1 Mortality varies greatly, depending on various 
factors including age, comorbid conditions, and stability on pre-
sentation. Patients with low-risk PE have a 1-year survival rate 
over 95%. In contrast, patients presenting with high risk PE and 
hemodynamic instability have an approximately 40% mortality 
rate within 90-days.2 In this review, we will discuss the basic pa-
thophysiology of PE, risk factors for developing PE, and standard 
diagnostic testing modalities. We will also cover risk stratification 
of patients presenting with PE and the implications for treatment 
and disposition.
PATHOPHYSIOLOGY 
PE occurs when clots formed in the deep venous system dislodge 
or break loose, travel through the heart, and become lodged in 
the pulmonary vasculature. While small PE can frequently lyse 
spontaneously, larger PE can cause a sudden and persistent rise in 
pulmonary artery pressure, which can lead to circulatory collapse.
 Clot formation usually begins at sites of tissue or vascular trau-
ma where recruited activated monocytes expose blood to tissue 
factor on their surfaces and overwhelm the body’s natural anti-
coagulant and fibrinolytic mechanisms. These deep venous throm-
bi (DVT), composed mainly of red blood cells, platelets, and fibrin, 
tend to form in the venous sinuses or cusps of the lower extremi-
ty deep veins. While the main concern is that part or all of a DVT 
will embolize to the pulmonary vasculature, the vascular conges-
tion caused by DVT also has multiple effects on the limb. There is 
often associated swelling and discomfort, as well as eventual loss 
of valve competency. This allows for lack of forward flow causing 
more swelling, stasis, and thrombus propagation. 
 A longer-term complication is “post-thrombotic syndrome” 
which can result if these changes persist over time. Post-throm-
botic syndrome consists of a constellation of symptoms including 
calf pain, swelling, and stasis skin changes, especially hyperpig-
mentation at the medial malleolus. It affects approximately half 
of patients who suffer DVT, although the onset can be delayed 
several years following DVT formation.3 
 Once a clot becomes lodged in the pulmonary vasculature, it 
causes obstruction. The extent of this obstruction, combined with 
the presence of any underlying cardiopulmonary disease are the 
most important factors in determining whether right ventricular 
dysfunction will develop.4 The blockage, combined with the re-
lease of vasoactive mediators, causes a sudden rise in pulmonary 
artery pressure, which increases right ventricular afterload. The 
right ventricle, a thin-walled structure compared to the robust 
left ventricle, can dilate and become hypokinetic in response to 
the rapid rise in afterload. Right ventricular dilatation can ulti-
mately lead to under-filling of the left ventricle as the interven-
tricular septum protrudes into the left ventricle, decreasing cardi-
ac output and coronary perfusion which, in turn, can lead to even-
tual circulatory collapse.4
RISK FACTORS FOR DVT AND PE 
There are multiple factors that can increase one’s chance of de-
veloping DVT and PE. These factors can be inherited, acquired over 
time, or provoked. Various inherited conditions increase a patient’s 
risk for venous thromboembolism (VTE), the most common of which 
are factor V Leiden and prothrombin gene mutation (G20210A) 
with population prevalences of approximately 4% to 5% and 2% 
to 4%, respectively.5,6 In patients with factor V Leiden, the incre-
ased risk of VTE is 2- to 7-fold in heterozygous individuals and up 
to 40-fold in those who are homozygous.7
 The most common acquired risk factors for VTE include: increas-
ing age, venous insufficiency, obesity, smoking, rheumatologic 
conditions, cardiovascular disease, previous VTE, and antiphos-
pholipid antibody syndrome. The mechanism behind increasing 
age appears to be that naturally circulating anticoagulants (pro-
tein C and protein S) decrease more than procoagulation factors 
over time, creating an increased prothrombotic state. This, com-
bined with increased venous stasis in the lower extremities, in-
creases the rates of DVT and PE in the elderly population. Obesity 
is a known risk factor for VTE, and data from the Nurses’ Health 
Study found that, among the most obese subjects (body mass in-
dex >35), there was a 6-fold increase in risk when compared to 
normal-weight subjects.8 This same study showed that hyperten-
sion and cigarette smoking were also associated with increased 
risk of idiopathic PE.9,10
 Provoking risk factors are those that create a significant in-
crease in VTE risk that can resolve once the provoking factor is 
eliminated. Provoking factors typically increase the risk of VTE 
more than other risk factors. Common provoking factors include: 
cancer, exogenous hormone use (in particular, recent initiation of 
estrogen-containing formulations), pregnancy/postpartum state, 
limb immobility, recent trauma or surgical procedure, and indwell-
ing catheters. In a national registry, the incidence of DVT and PE 
in patients with cancer was twice that of patients without can-
cer.11 Cancer is considered a provoking factor because the risk of 
VTE is elevated in patients with active cancer, but a history of 
treated cancer in remission is not associated with increased VTE 
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risk. Exogenous hormone use has long been known to be associ-
ated with increased risk of VTE. In patients taking oral contracep-
tives there is a 3- to 4-fold increased risk of VTE, and those using 
“third-generation” progesterone formulations are especially at 
risk.12 The increased risk of VTE during pregnancy starts in the 
first trimester and continues through the postpartum period, with 
the greatest risk during the first 2 weeks postpartum.13 The in-
creased risk of VTE associated with prolonged limb immobility 
typically occurs after about 72 hours of acute limb immobility.14 
It is also important to note that provoking factors can interact 
with other risk factors to increase VTE likelihood more than either 
factor would individually.15 
INITIATING THE DIAGNOSTIC WORKUP: PRE-
TEST PROBABILITY ASSESSMENT 
The first step in the diagnostic workup for PE and DVT is deter-
mining the patient’s pre-test probability of the diagnosis. The pa-
tient’s pre-test probability determines whether testing is indicat-
ed at all, and which tests should be performed. While multiple 
prediction rules for PE exist, the two most commonly used are 
the Wells score and the revised Geneva score for PE. The Wells 
score (Table 1) consists of 6 objective questions and one subjec-
tive question asking whether “PE is the most likely diagnosis.” 
Based on the score (points are awarded for each positive answer) 
pre-test probability of PE may be assigned as either low (<2 points), 
intermediate (2 to 6), or high (>6). Alternatively, the Wells score 
can be dichotomized into low probability (less than or equal to 4 
points) and high probability (>4), which some argue is more eas-
ily applied to clinical decision-making.16
 The revised Geneva score (Table 2) consists entirely of objective 
questions. Zero to 3 points is considered low probability, 4 to 10 
points is intermediate probability, and more than 11 points is con-
sidered high probability of PE. Both scores have been validated 
and perform similarly in clinical practice. However, studies also 
show that clinical gestalt assessed by an experienced clinician is 
just as accurate as these formal decision rules.16 
 The pulmonary embolism rule-out criteria (PERC) was designed 
to identify patients in whom the risk of testing outweighs the 
benefits (the “test threshold”, which for PE was calculated as a 
2% prevalence). The PERC consists of eight objective variables 
that can be applied to patients with low clinical (pre-test) proba-
bility of PE (Table 3).17 The sensitivity of the PERC rule is 96% to 
100% and specificity is 15% to 27%. In the initial derivation and 
validation study of low and very-low probability patients, the pre-
valence of PE in patients that were PERC negative was <1.5%.17 
The PERC was subsequently validated in an NIH-funded multi-
center study of 8,138 patients. Twenty percent (n=1,666) of en-
rolled patients had a low clinical probability of PE and were PERC 
negative.18 Of this group, 15 patients were positive for VTE within 
45 days of initial presentation—a false negative rate of <1%, with 
an upper confidence limit of <2%. The sensitivity was 97.4% 
and the specificity was 21.9%. The authors therefore concluded 
that a low pretest probability and a negative PERC effectively 
rules out PE with a false negative rate lower than the test-thresh-
old. The PERC rule has now been incorporated into guidelines for 
the diagnosis of PE.18,19 
Table 1. Wells score for PE
Variable Points
Previous PE or DVT +1.5
Heart rate >100 bpm +1.5
Recent surgery or immobilization +1.5
Clinical signs of DVT +3
Hemoptysis +1
Cancer +1
Alternative diagnosis less likely than PE +3
Probability of PE Score Prevalence of PE
Low ≤4 7.8%
High >6 61%
PE, pulmonary embolism; DVT, deep venous thrombi.  
Table 2. Revised Geneva score for PE
Variable Points
Age >65 yr +1
Previous venous thromboembolism +3
Surgery requiring anesthesia or fracture of lower limb in the  
   past month
+2
Active malignancy +2
Unilateral leg pain +3
Hemoptysis +2
Unilateral leg edema +4
Heart rate 75-94 bpm +3
Heart rate >95 bpm +5
Probability of PE Score Prevalence of PE
Low ≤3 8%
High >11 74%
PE, pulmonary embolism. 
Table 3. Pulmonary embolism rule-out criteria 
Variable
Age <50 yr
Pulse <100 bpm
SaO2 >94%
No unilateral leg swelling
No hemoptysis
No recent trauma or surgery
No prior pulmonary embolism/ deep venous thrombi
No hormone use
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TESTING AND DIAGNOSIS
DVT diagnosis 
The diagnostic test of choice for detection of proximal DVT is ve-
nous ultrasonography, with loss of vein compressibility being di-
agnostic of DVT. This modality is readily available in the emergen-
cy department at all times and poses little to no risk to the pa-
tient. A meta-analysis assessing emergency physicians’ ability to 
diagnose DVT on ultrasound confirmed that emergency physi-
cians’ weighted mean sensitivity and specificity for DVT were on 
par with radiology-performed studies (96.1% and 96.8% respec-
tively).20 Since approximately half of patients with PE have no 
imaging evidence of DVT, a negative venous ultrasound is not 
sufficient to rule out PE. However, evidence of DVT on ultrasound 
along with signs and symptoms of PE is considered diagnostic, 
and sufficient for initiation of treatment. Accordingly, analyses 
suggest that a non-invasive strategy combining ultrasound and 
D-dimer testing (below) as the first diagnostic tests for PE may 
be the most cost-effective approach.21
 For most patients in whom VTE is a concern, the most appro-
priate first test is usually the D-dimer. This test analyzes blood for 
a breakdown product of cross-linked fibrin that is detectable when 
plasmin breaks down organized clot. The test is highly sensitive 
for VTE (95% sensitive when using the Food and Drug Adminis-
tration (FDA)-approved cutoff (typically <500 ng/mL). A negative 
D-dimer effectively rules out PE, with post-test probability <2%, 
in patients with non-high pre-test probability.22 However, D-di-
mer assays are poorly specific (typically 40% to 50%), so further 
testing is needed to rule out VTE in a large proportion of patients 
who have a positive D-dimer. D-dimer results are even more likely 
to be elevated in certain states, so the usefulness of the test is 
limited in the elderly (>80 years), pregnant women (especially in 
the third trimester), patients with sickle cell anemia, and those 
with major trauma or surgery in the past month.22,23 There has 
been some research into utilizing adjusted D-dimer values accord-
ing to age, in which the cut off of a positive D-dimer for patients 
over 50 years was calculated as: age multiplied by 10. This has 
been evaluated prospectively and found be associated with low 
risk of clinically significant PE or death, however more research is 
still needed to validate this adjustment for incorporation into ev-
eryday practice.23 
PE diagnosis
The standard imaging modality for diagnosis of PE is contrast en-
hanced computed tomography pulmonary angiography (CTPA). 
Modern computed tomography scanners provide excellent reso-
lution and enable the detection of smaller thrombi than previ-
ously possible. PE are visualized as filling defects (gray) in con-
trast-filled (white) pulmonary arteries and most often arise at 
sites of bifurcation or vessel narrowing. One of the largest diag-
nostic studies of CTPA for PE was the landmark PIOPED (Prospec-
tive Investigation of Pulmonary Embolism Diagnosis)-II study, 
which showed the sensitivity of CTPA was 83% to 90% depend-
ing on the location of the PE and whether computed tomograph-
ic venography of the lower extremities was included.24 CTPA was 
found to have specificity >95% in this study. Subsequent out-
comes studies confirmed that CTPA can safely rule out PE in pa-
tients with a high pre-test probability of PE or a positive D-dimer 
with fewer than 2% of patients diagnosed with PE in the three 
months after a negative CTPA.25
 An alternative to CTPA is ventilation/perfusion lung scanning, 
which is particularly useful for patients in whom CTPA is contra-
indicated, such as: patients with chronic kidney disease, contrast 
dye allergy, or radiation concerns in pregnancy. This involves a ra-
dionucleotide perfusion scan and a ventilation scan. If the perfu-
sion scan is normal (i.e., shows no perfusion defects), this effec-
tively rules out PE and the ventilation portion of the scan is un-
necessary. When the perfusion scan is abnormal, the ventilation 
portion of the scan must be performed. A minimum of two wedge-
shaped defects in a segmental or larger vascular distribution along 
with signs of normal ventilation in the same segments defines a 
high-probability scan, which is diagnostic of PE. Unfortunately, as 
many as two thirds of patients will have a non-diagnostic scan, 
which is neither normal nor high-probability. This is the main rea-
son that ventilation/perfusion scanning was supplanted by CTPA 
as the first imaging test for PE.
 Patients with severe PE can present with significant hemody-
namic instability, making diagnosing PE with imaging difficult. Pa-
tients with large PE are preload dependent due to impaired left 
ventricular filling, thus interventions to increase preload, like bolus-
es of isotonic intravenous fluid, are recommended, while interven-
tions that decrease preload, like positive pressure ventilation and 
diuresis may be harmful and should be avoided if possible. In pa-
tients with high probability of PE who are unable to obtain defini-
tive diagnostic imaging (e.g., CTPA) within 2 hours, guidelines rec-
ommend empiric anticoagulation.26 Similarly, in patients with in-
termediate probability of PE empiric anticoagulation is recommend-
ed in cases where diagnostic imaging will take longer than 24 hours.26 
RISK STRATIFICATION
The severity of PE varies widely. Patients with PE may be asymp-
tomatic or may present with complete cardiovascular collapse. 
For low-risk PE, initiation of anticoagulation and discharge home 
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may be appropriate, while for high-risk PE, thrombolysis, surgical 
thromboembolectomy and admission to the intensive care unit 
may be necessary. Risk stratification after PE diagnosis is there-
fore of paramount importance. 
 The main determinants of PE severity are: presence of right 
heart strain either on echocardiography or computed tomogra-
phy, myocardial damage based on troponin elevation, and overall 
clot burden. Although the overall clot burden appears to have 
only a variable relationship to outcomes, large PE are typically 
associated with worse outcomes than smaller or segmental PE.27 
One must also consider the general overall health of the patient 
and take into account age and presence of comorbid illness that 
may affect prognosis. While there is variability in the classifica-
tions systems used to define short-term risks from PE, for the pur-
poses of this discussion we will categorize patients as low-risk, 
intermediate-risk, and high-risk.28,29
High risk
Patients with PE who present with hypotension, syncope, brady-
cardia, or the inability to maintain adequate oxygenation are at 
risk for sudden death, even with appropriate treatment. Patients 
with large PE and residual clot present in the heart (“clot-in-tran-
sit”) or iliofemoral veins should also be considered at high risk for 
decompensation. High-risk patients often require emergent inter-
vention and admission to the intensive care unit.
Intermediate risk
Patients who presents with end organ damage but are hemody-
namically stable can be considered intermediate risk. Right heart 
strain on echocardiography, in the setting of a large PE, is also 
associated with an increased risk of clinical deterioration and/or 
short-term death.28 Other factors, such as an elevated troponin 
indicating cardiac ischemia, altered mental status, and the pres-
ence of co-morbid illness have also been correlated with early 
clinical deterioration and higher incidence of short-term death.28,30
Low risk
Patients found to have PE without evidence of end organ damage 
or hemodynamic instability may be able to be safely discharged 
early after initiation of anticoagulation. In an analysis of 298 
consecutive patients with PE, we found that 2/3 of patients suf-
fered no clinical deterioration and required no hospital-based in-
terventions after PE. This suggests that a large proportion of pa-
tients derive no benefit from hospitalization after PE, and may be 
safe for discharge from the ED. In our analysis, similar to a pro-
spective study by Sanchez et al.,28 hypotension, hypoxia, history 
of coronary artery disease, evidence of right heart strain, and re-
sidual DVT were all found to be independently associated with 
clinical deterioration. Patients who present with none of these 
risk factors are likely at low risk for early clinical deterioration 
and are ideal candidates for early discharge after initiation of an-
ticoagulation.29,31
TREATMENT AND DISPOSITION
For all patients with PE who do not have a significant contraindi-
cation, anticoagulation treatment is essential in halting the prop-
agation of thromboembolism. There is now a wide range of anti-
coagulation options and other interventions available depending 
on a patient’s initial presentation, risk of early clinical deteriora-
tion, and mortality. For most patients, in particular low risk pa-
tients, treatment with a long acting oral or subcutaneous antico-
agulant is indicated. However, for some patients, in particular 
those likely to undergo an intervention or thrombolysis or those 
at high risk of bleeding, the ability to rapidly “turn off” anticoag-
ulation may be beneficial. In these cases, unfractionated heparin 
(UFH) is the anticoagulant of choice.
Anticoagulation
Anticoagulation does not dissolve clot that already exists, but it 
decreases new thrombus formation while permitting the body’s 
natural fibrinolytic mechanisms to lyse existing clot. For patients 
with acute PE and no active cancer, guidelines recommend initia-
tion of a direct acting oral anticoagulant (DOAC): apixaban, dabi-
gatran, edoxaban or rivaroxaban.26 Of these, apixaban and rivar-
oxaban do not require ‘bridging’ therapy with heparin, so are bet-
ter suited for initiation of therapy in ED patients. Compared with 
long-term warfarin therapy, these DOAC agents are associated 
with similar rates of recurrent PE but slightly lower rates of treat-
ment-associated hemorrhage, in particular, intracranial hemor-
rhage. DOACs are administered orally, provide rapid onset of ac-
tion, and do not require routine laboratory coagulation monitor-
ing. These medications have few interactions and are generally 
associated with lower rates of major bleeding, making them pref-
erable to warfarin.32 
 Currently, four DOACs have received US FDA approval for the 
treatment of VTE. Distinctions between the four US FDA approved 
DOACs must be considered when determining treatment recom-
mendations. Dabigatran, is a direct thrombin (factor II) inhibitor 
approved for the treatment of acute VTE after initial treatment 
with heparin.17 Apixaban, edoxaban, and rivaroxaban, are factor 
Xa inhibitors and approved for treatment of VTE. However, while 
apixaban and rivaroxaban are approved as monotheraphy, edoxa-
ban requires a heparin bridge similar to dabigatran. The initiation 
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dose of apixaban is 10 mg twice daily for 7 days followed by 5 
mg twice daily after that period. The initiation dose of rivaroxa-
ban is 15 mg orally, twice daily, followed by 20 mg daily after 21 
days. All of the DOACs should be used with caution in patients 
with severe liver or kidney disease, and studies of high-risk sub-
groups of patients (e.g., antiphospholipid antibody) are limited. 
 None of the DOACs have been extensively tested in patients 
with active cancer, so low molecular weight heparin (LMWH) is 
still recommended as initial therapy for these patients. Trials are 
ongoing to assess the efficacy and safety of the DOACs in this 
population. 
 As above, low risk patients can often be discharged from the 
ED, an emergency department observation unit, or inpatient floor 
within 24 hours of diagnosis. Close follow-up and strict return 
instructions are required. However, the oral bioavailability of DO-
ACs and the associated ability to initiate treatment without in-
travenous or subcutaneous injections (with apixaban or rivaroxa-
ban) may help facilitate the outpatient treatment of PE and DVT. 
 The main clinical concern about the DOAC agents has been the 
lack of an effective reversal agent. However, this concern is large-
ly mitigated by the lower risk of major and intracranial bleeding 
associated with the DOACs. In addition, idarucizumab, a mono-
clonal antibody designed for the reversal of anticoagulant effects 
of dabigatran, was recently approved by the US FDA. Studies of 
andexanet alfa, a recombinant protein designed to reverse the 
anticoagulant activity of direct and indirect factor Xa inhibitors is 
currently being studied and may be approved for use in the near 
future. 
 Heparins bind to antithrombin, thus increasing its activity and 
markedly accelerating inactivation of thrombin, factor Xa, and 
factor IXa. Both unfractionated intravenous heparin and LMWH 
are effective for the treatment of acute PE. In patients with nor-
mal hepatic function and no history of heparin induced thrombo-
cytopenia (HIT), UFH can be initiated with an IV bolus of 80 U/kg, 
followed by a continuous infusion at 18 U/kg/hr, with a target 
activated partial thromboplastin time between 1.5 and 2.5 times 
the control value (60 to 80 seconds). The short half-life of UFH is 
advantageous for patients who may require embolectomy or 
thrombolysis or who are at high risk for bleeding (e.g., recent high 
risk surgery). 
 LMWHs is composed of small fragments of heparin that bind 
strongly to antithrombin working in the same way as heparin, but 
with improved bioavailability, a longer half-life, dose dependent 
clearance, and lower rates of HIT. Thus LWMH can be adminis-
tered once or twice daily without the need for laboratory moni-
toring. The most commonly used LMWHs include enoxaparin, at 
a dose of 1 mg/kg twice daily; dalteparin, at a dose of 200 U/kg 
daily or 100 to 125 U/kg twice daily; and tinzeparin, at a dose of 
175 U/kg daily. LMWHs are associated with a slightly lower rate 
of anticoagulation associated bleeding than UFH, with a compa-
rable risk of recurrent PE. Thus, for patients who do not require 
thrombolysis or an invasive procedure, LMWHs are generally pre-
ferred over UFH. The subcutaneous administration route for LM-
WHs offers the possibility of treatment at home and thus allows 
for earlier hospital discharge.33 
 LMWH is also preferred over warfarin for patients with VTE 
and active cancer. In a randomized trial, monotherapy with dalte-
parin was shown to reduce VTE recurrence compared to long-term 
warfarin therapy, with 9% of dalteparin patients suffering a re-
currence compared to 17% of warfarin patients.33 LMWH is also 
preferred treatment in pregnancy, as warfarin is teratogenic and 
contraindicated. 
 For initial treatment of PE in patients with known HIT, fonda-
parinux, an anticoagulant that binds antithrombin and inhibits 
factor Xa is another alternative to the DOACs. Fondaparinux had 
no known effect on platelet function and does not cross-react 
with heparin-induced antibodies. Dosing is weight-based, from 5 
to 10 mg daily as a subcutaneous injection. Lepirudin and argatro-
ban are intravenous direct thrombin inhibitors that bind directly 
to fibrin-associated thrombin or fibrin degradation products. 
 Warfarin, now a second line option for the long-term treat-
ment of PE, produces hemostatically defective vitamin K-depen-
dent coagulant proteins (factors II, VII, IX, and X). The anticoagu-
lant response is variable among patients and thus frequent moni-
toring of the patient’s prothrombin time/international normalized 
ratio is required to maintain it within the therapeutic window of 
2 to 3. Warfarin interacts with multiple other drugs and with vi-
tamin K-containing foods and requires heparin bridging.
Treatment of high-risk patients
While the mainstay of treatment for all patients presenting with 
PE is anticoagulation, high-risk patients may require additional 
treatment measures to reduce the clot burden. Systemic intrave-
nous thrombolysis has been shown to improve mortality and he-
modynamic stability when used for patients with high risk (mas-
sive) and high-intermediate risk (submassive) PE.32 However, sys-
temic thrombolysis is associated with a high risk of hemorrhage. 
Thus, its use should be limited to high-risk, hemodynamically un-
stable PE patients and select intermediate-risk PE patients with a 
low bleeding risk. 
 Alteplase (t-PA) and tenecteplase are two thrombolytic agents 
that can be used in treatment of PE. Only alteplase is US FDA ap-
proved for the treatment of massive PE. Due to its short half-life 
of 4 to 6 minutes, alteplase requires a continuous IV infusion. An 
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initial bolus of 15 mg followed by an additional 85 mg over 2 
hours is standard dosing. For hemodynamically unstable patients, 
this relatively lengthy 2 hours infusion may be too slow and im-
practical. Here tenecteplase offers an alternative, with a longer 
20 to 24 minutes half-life that is delivered in a single, weight-based 
bolus dose. Tenecteplase, however, is not currently FDA approved 
for VTE treatment, although it was used in two major randomized 
trials of PE thrombolysis.34,35 
 Catheter-directed thrombolysis may attenuate the bleeding risk 
associated with systemic thrombolysis. Catheter-directed throm-
bolysis involves catheter placement adjacent to the PE, with local 
infusion of thrombolytics into affected pulmonary arteries. Me-
chanical and ultrasonic clot disruption can be used to assist in 
thrombolysis. This targeted technique offers the benefit of both 
local delivery and lower drug dose (typically 10 to 20 mg t-PA in-
fused over 12 to 24 hours). In addition, the presence of catheters 
allows for PA pressure monitoring which can be used to guide 
discontinuation of therapy.36 As this procedure is relatively new, 
robust outcome data on patients treated with catheter-directed 
thrombolysis are lacking, with only one small randomized trial 
published. However, larger registry studies and meta-analyses of 
case series demonstrate clinical effectiveness and minimal bleed-
ing risk associated with catheter directed thrombolysis.36,37
 Surgical thromboembolectomy, performed via a median ster-
notomy can be effective for select patients with large PE, espe-
cially when performed at experienced centers.38 Historically, this 
procedure has typically been reserved for those with massive, he-
modynamically unstable PE who either had an absolute contrain-
dication or failed thrombolysis. Mortality has improved in recent 
years and is better if performed prior to the development of car-
diogenic shock and end organ damage, but is still around 20% 
likely due to the severe illness of patients referred for surgery.38,39 
 Highly specialized centers can also perform percutaneous suc-
tion thromboembolectomy. This involves cannulation of the ve-
nous system in two places for aspiration of the clot and reinfu-
sion of blood following filtration and is typically reserved for pa-
tients with large proximal (e.g., saddle) emboli or clot-in-tran-
sit.36,37 
PE response ‘PE response teams’
Some large academic centers have created multidisciplinary PE 
response teams (PERTs). Modeled on other rapid response teams, 
PERTs meet in real-time to discuss optimal therapy for patients 
presenting with life threatening PE. These multidisciplinary teams 
usually involve specialists in cardiology, cardiovascular surgery, 
emergency medicine, hematology, interventional radiology, pul-
monary/critical care, vascular medicine and surgery.39 PERTs are 
designed to facilitate the efficient mobilization of resources and 
offer the benefit of multi-specialty expertise to patients with high- 
and intermediate-risk PE. The PERT from Massachusetts General 
Hospital, where the PERT concept originated, recently reported 
their experience treating 394 patients with high and intermedi-
ate risk PE. The PERT paradigm may become the new standard of 
care for patients with PE.39,40 The PERT can be activated from any 
area of the hospital and in some cases prior to the arrival of trans-
fer patients when severe PE is identified. As seen in Fig. 1, after 
activation there is a real-time meeting of a multidisciplinary team, 
which discusses appropriate treatment options and disposition 
and then makes their recommendations. The PERT activation mo-
bilizes resources needed to make room in the intensive care unit, 
operating room, and/or angiography suite when emergent inter-
vention is needed and greatly facilitates timely care of the sickest 
patients presenting with PE.
CONCLUSION
PE diagnosis and treatment remains challenging for emergency 
physicians. Symptoms can be vague or non-existent, and the clin-
ical presentation shares features with many other common diag-
noses. Diagnostic testing varies based on pretest probability and 
many testing modalities are not without their own risks. Recent 
advances in treatment have emerged as have multidisciplinary 
teams to assess and tailor treatment to individual patients needs. 
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Fig. 1. Pulmonary embolism response team (PERT) approach. ED, emer-
gency department; ICU, intensive care unit; PE, pulmonary embolism.
ED, ICU, floor team
Immediate conference with PE specialists:
cardiology, cardiac surgery, diagnostic radiology, emergency medicine, 
hematology, interventional radiology, pulmonary/critical care,  
vascular medicine, vascular surgery
Disposition and treatment plan
Activate PERT
Referring hospital
Severe PE identified
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